Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 4-5, 2009, Pages 580-590

  Bansal, Tripta ^a,b   Mishra, Gautam ^b   Jaggi, Manu ^b   Khar, Roop K ^a   Talegaonkar, Sushama ^a  

^a HAMDARD UNIVERSITY   (India)

^b DABUR RESEARCH FOUNDATION   (India)

Author keywords

Biliary excretion; Bioavailability; Irinotecan (CPT 11); P glycoprotein; Verapamil

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; IRINOTECAN; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TRANSPORT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BILIARY TRACT; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; P-GLYCOPROTEINS; RATS; RATS, WISTAR; SPECTROPHOTOMETRY, ULTRAVIOLET; VERAPAMIL;

EID: 59549094629     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.12.005     Document Type: Article

References (40)

1. Araki E., Ishikawa M., Iigo M., Koide T., Itabashi M., and Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res. 84 (1993) 697-702
2. Arimori K., Kuroki N., Hidaka M., Iwakiri T., Yamsaki K., Okumura M., Ono H., Takamura N., Kikuchi M., and Nakano M. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm. Res. 20 (2003) 910-917
3. Bansal, T., Awasthi, A., Jaggi, M., Khar, R.K., Talegaonkar, S., in press a. Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. Talanta. Available online 4 May 2008.
4. Bansal, T., Awasthi, A., Jaggi, M., Khar, R.K., Talegaonkar, S., in press b. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. Life Sci. Available online 24 June 2008.
5. Breedveld P., Beijnen J.H., and Schellens J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27 (2006) 17-24
6. Candussio L., Decorti G., Crivellato E., Granzotto M., Rosati A., Giraldi T., and Bartoli F. Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin. Life Sci. 71 (2002) 3109-3119
7. Choi J.S., and Li X. The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur. J. Pharm. Sci. 24 (2005) 95-100
8. Chu X.Y., Kato Y., Niinuma K., Sudo K.I., Hakusui H., and Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther. 281 (1997) 304-314
9. Chu X.Y., Kato Y., Ueda K., Suzuki H., Niinuma K., Tyson C.A., Weizer V., Dabbs J.E., Froehlich R., Green C.E., and Sugiyama Y. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 58 (1998) 5137-5143
10. Dantzig A.H., de Alwis D.P., and Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev. 55 (2003) 133-150
11. de Forni M., Bugat R., Chabot G.G., Culine S., Extra J.M., Gouyette A., Madelaine I., Marty M.E., and Mathieu-Boue A. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 54 (1994) 4347-4354
12. Drengler R.L., Kuhn J.G., Schaaf L.J., Rodriguez G.I., Villalona-Calero M.A., Hammond L.A., Stephenson Jr. J.A., Hodges S., Kraynak M.A., Staton B.A., Elfring G.L., Locker P.K., Miller L.L., Von Hoff D.D., and Rothenberg M.L. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J. Clin. Oncol. 17 (1999) 685-696
13. Gupta E., Lestingi T.M., Mick R., Ramirez J., Vokes E.E., and Ratain M.J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54 (1994) 3723-3725
14. Gupta E., Safa A.R., Wang X., and Ratain M.J. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res. 56 (1996) 1309-1314
15. Horikawa M., Kato Y., Tyson C.A., and Sugiyama Y. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab. Pharmacokinet. 17 (2002) 23-33
16. Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., and Grove J.R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88 (1999) 28-33
17. Itoh T., Itagaki S., Sumi Y., Hirano T., Takemoto I., and Iseki K. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2. Cancer Chemother. Pharmacol. 55 (2005) 420-424
18. Iyer L., Ramirez J., Shepard D.R., Bingham C.M., Hossfeld D.K., Ratain M.J., and Mayer U. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother. Pharmacol. 49 (2002) 336-341
19. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., and Schinkel A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92 (2000) 1651-1656
20. Kehrer D.F., Mathijssen R.H., Verweij J., de Bruijn P., and Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol. 20 (2002) 3122-3129
21. Kruijtzer C.M., Beijnen J.H., Rosing H., ten Bokkel Huinink W.W., Schot M., Jewell R.C., Paul E.M., and Schellens J.H. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20 (2002) 2943-2950
22. Liu Y., Huang L., Hoffman T., Gosland M., and Vore M. MDR1 substrates/modulators protect against beta-estradiol-17beta-d-glucuronide cholestasis in rat liver. Cancer Res. 56 (1996) 4992-4997
23. Lokiec F., Canal P., Gay C., Chatelut E., Armand J.P., Roche H., Bugat R., Goncalves E., and Mathieu-Boue A. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother. Pharmacol. 36 (1995) 79-82
24. Luo F.R., Paranjpe P.V., Guo A., Rubin E., and Sinko P. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab. Dispos. 30 (2002) 763-770
25. Mathijssen R.H., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., and Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7 (2001) 2182-2194
26. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 13 (2006) 1859-1876
27. Schoemaker N.E., Kuppens I.E., Huinink W.W., Lefebvre P., Beijnen J.H., Assadourian S., Sanderink G.J., and Schellens J.H. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemother. Pharmacol. 55 (2005) 263-270
28. Soepenberg O., Dumez H., Verweij J., Semiond D., deJonge M.J., Eskens F.A., ter Steeg J., Selleslach J., Assadourian S., Sanderink G.J., Sparreboom A., and van Oosterom A.T. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. J. Clin. Oncol. 23 (2005) 889-898
29. Stephens R.H., O'Neill C.A., Warhurst A., Carlson G.L., Rowland M., and Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. 296 (2001) 584-591
30. Stewart C.F., Leggas M., Schuetz J.D., Panetta J.C., Cheshire P.J., Peterson J., Daw N., Jenkins III J.J., Gilbertson R., Germain G.S., Harwood F.C., and Houghton P.J. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 64 (2004) 7491-7499
31. Stewart C.F., Zamboni W.C., Crom W.R., and Houghton P.J. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother. Pharmacol. 40 (1997) 259-265
32. Takemoto I., Itagaki S., Chiba M., Itoh T., Hirano T., and Iseki K. Characterization of secretory intestinal transport of the lactone form of CPT-11. Cancer Chemother. Pharmacol. 57 (2006) 129-133
33. Tobin P.J., Hong Y., Seale J.P., Rivory L.P., and McLachlan A.J. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. J. Pharm. Pharmacol. 57 (2005) 39-45
34. Troutman M.D., and Thakker D.R. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm. Res. 20 (2003) 1192-1199
35. Varma M.V., Ashokraj Y., Dey C.S., and Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 48 (2003) 347-359
36. Varma M.V., and Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 25 (2005) 445-453
37. Yamamoto W., Verweij J., de Bruijn P., de Jonge M.J., Takano H., Nishiyama M., Kurihara M., and Sparreboom A. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs 12 (2001) 419-432
38. Yamazaki M., Neway W.E., Ohe T., Chen I.-W., Rowe J.F., Hochman J.H., Chiba M., and Lin J.H. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and permeability of in vivo results. J. Pharmacol. Exp. Ther. 296 (2001) 723-735
39. Yang X., Hu Z., Chan S.Y., Chan E., Goh B.C., Duan W., and Zhou S. Novel agents that potentially inhibit irinotecan-induced diarrhea. Curr. Med. Chem. 12 (2005) 1343-1358
40. Zamboni W.C., Houghton P.J., Thompson J., Cheshire P.J., Hanna S.K., Richmond L.B., Lou X., and Stewart C.F. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin. Cancer Res. 4 (1998) 455-462